Unternehmen Vinings Holdings Inc. Other OTC
Aktien
NDYN
US92744A1051
NDYN
Pharmazeutika
Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
David Mehalick
CEO | Chief Executive Officer | 56 | 28.10.22 |
Brian Cogley
DFI | Director of Finance/CFO | 38 | 17.05.23 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 28.10.22 |
Colleen Delaney
CTO | Chief Tech/Sci/R&D Officer | 57 | 30.08.23 |
Christine Sheehy
CMP | Compliance Officer | 57 | 28.10.22 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Director/Board Member | 62 | 28.10.22 | |
Director/Board Member | 55 | 28.10.22 | |
Christine Sheehy
CMP | Compliance Officer | 57 | 28.10.22 |
Gene Salkind
BRD | Director/Board Member | 70 | 28.10.22 |
Chris Calise
BRD | Director/Board Member | 51 | 28.10.22 |
David Mehalick
CEO | Chief Executive Officer | 56 | 28.10.22 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 28.10.22 |
Director/Board Member | 56 | 28.10.22 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 37 118 593 | 25 373 891 ( 68,36 %) | 0 | 68,36 % |
Unternehmenskontakt
Coeptis Therapeutics Holdings, Inc.
105 Bradford Road Suite 420
15090, Wexford
+
http://www.coeptistx.com![Straße Vinings Holdings Inc.(NDYN)](https://cdn.zonebourse.com/static/address/111314388.png)
Sektor
% 1. Jan. | Kap. | |
---|---|---|
+55,19 % | 801 Mrd. | |
+47,26 % | 631 Mrd. | |
-6,09 % | 359 Mrd. | |
+21,92 % | 337 Mrd. | |
+18,40 % | 245 Mrd. | |
+3,64 % | 231 Mrd. | |
+12,98 % | 219 Mrd. | |
+10,86 % | 171 Mrd. | |
-2,78 % | 161 Mrd. |